BioSpace News Archive

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Dr. Rob Quinn as Chief Financial Officer, effective immediately.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, reported its condensed consolidated financial results for the six-month period ending 30 June 2022, along with a year-to-date business update and an outlook.

Calibre Scientific is pleased to announce the acquisition of Achrom, a Belgium-based distributor of chromatography consumables, equipment, and accessories.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York Palace Hotel.

Cambrex announced the completion of the first phase of its $30 million investment in its small molecule active pharmaceutical ingredient manufacturing facility in High Point, North Carolina.

Santhera Pharmaceuticals and ReveraGen announce that JAMA Neurology has published positive results of the 24-week primary efficacy and safety analysis from the VISION-DMD study evaluating vamorolone, an investigational drug for the treatment Duchenne muscular dystrophy.

Photocure ASA, the Bladder Cancer Company, announced the appointment of Dr. Anders Neijber to the position of Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D, effective September 1, 2022.

Global molecular diagnostics innovator, Sense Biodetection, announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform.

Helsinn Group and Juniper Biologics Pte Ltd announced the signing of an exclusive distribution license and supply agreement to register, distribute, promote, market and sell LEDAGA® in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults.